Non-ventilatory-based strategies in the management of acute respiratory distress syndrome

Journal of Trauma - Injury, Infection and Critical Care

Volumn 57, Issue 4, 2004, Pages 915-924

  Klein, Yoram ^a   Blackbourne, Lorne ^a   Barquist, Erik S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ARDS; Complications; Review; Treatment

Indexed keywords

ATRACURIUM; LUNG SURFACTANT; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; ROCURONIUM; STEROID; VECURONIUM;

ARTIFICIAL VENTILATION; BODY POSTURE; CLINICAL TRIAL; EXTRACORPOREAL OXYGENATION; FLUID THERAPY; HUMAN; LUNG ARTERY PRESSURE; LUNG PRESSURE; MORTALITY; OXYGENATION; PATIENT POSITIONING; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; RESPIRATORY DISTRESS SYNDROME; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADULT; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; FLUID THERAPY; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; MULTIPLE TRAUMA; PROGNOSIS; PRONE POSITION; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 7244259190     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000136690.34310.9D     Document Type: Review

References (132)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;ii:320-323.
2. James PM, Anderson RW, Bredenberg CE, et al. The evaluation and therapeutic management of refractory shock in man. Mil Med. 1967;132:419-425.
3. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Am J Respir Crit Care Med. 1994;149:818-824.
4. Davidson TA, Caldwell ES, Curtis JR, et al. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA. 1999;281:354-360.
5. Herridge MS, Cheung AM, Tansley CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. NEJM. 2003;348:683-693.
6. Milberg JA, Davis DR, Steinberg KP, et al. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA. 1995;273:306-309.
7. Hudson LD, Steinberg KP. Epidemiology of acute lung injury and ARDS. Chest 1999;116:74S-82S.
8. Davidson TA, Rubenfeld GD, Caldwell ES, Hudson LD, Steinberg KP. The effect of acute respiratory distress syndrome on long-term survival. Am J Respir Crit Care Med. 1999;160:1838-1842.
9. The Acute Respiratory Distress Network (ARDSNET). Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. NEJM 2000;342:1301-1308.
10. Weinert CR, Gross CR, Marinelli WA. Impact of randomized trial results on acute lung injury ventilator therapy in teaching hospitals. Am J Respir Crit Care Med. 2003;167:1304-1309.
11. Bulger EM, Jurkovich GJ, Gentilello LM, Maier RV. Current clinical options for the treatment and management of acute respiratory distress syndrome. J Trauma. 2000;48:562-72.
12. Ferguson ND, Meade MO, Hallett DC, Stewart TE. High values of the pulmonary artery occlusion pressure in patients with acute lung injury and acute respiratory distress syndrome. Intensive Care Med. 2002;28:1073-1077.
13. Simmons RS, Berdine GG, Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis. 1987;135:924-929.
14. Schuster DP. The case for and against fluid restriction and occlusion pressure reduction in adult respiratory distress syndrome. New Horizons. 1993;1:478-88.
15. Matthay MA: Alveolar fluid clearance in patients with ARDS: does it make a difference? Chest 2002 Dec; 122(6 Suppl):340S-343S.
16. Frank JA, Pittet JF, Lee H, Godzich M, Matthay MA. High tidal volume ventilation induces NOS2 and impairs cAMP-dependent air space fluid clearance. Am J Physiol Lung Cell Mol Physiol. 2003;284:L791-8.
17. Reising CA, Chendrasekhar A, Wall PL, et al. Continuous dose furosemide as a therapeutic approach to acute respiratory distress syndrome. J Surg Res. 1999;82:56-60.
18. Humphrey H, Hall J, Sznajder I, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest. 1990;97:1176-1180.
19. Mitchell JP, Schuller D, Calandrino FS, et al. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis. 1992;145:990-998.
20. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336:912-918.
21. Geer RT, Soma LR, Barnes C, et al. Effects of albumin and/or furosemide therapy on pulmonary edema induced by hydrochloric acid aspiration in rabbits. J Trauma. 1976;16:788-791.
22. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002;30:2175-82.
23. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med. 2004;32:755-759.
24. Tullis JL. Albumin: 2. Guidelines for clinical use. JAMA. 1977;237:460-463.
25. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis. 1993;147:218-233.
26. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest. 1991;88:1976-1981.
27. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med. 1999;160:1843-1850.
28. Thomassen MJ, Meeker DP, Antal JM, Conners MJ, Wiedermann HP. Synthetic surfactant (Exosurf) inhibits endotoxin-stimulated cytokine secretion by human alveolar macrophages. Am J Respir Cell Mol Biol. 1992;7:257-260.
29. Weg JG, Balk RA, Tharatt S, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA. 1994;272:1433-1438.
30. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. NEJM. 1996;334:1417-1421.
31. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155:1309-1315.
32. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
33. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996.
34. Gerlach H, Rossaint R, Pappert D, et al. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest. 1993;23:499-502.
35. Frostell CG, Blomquvist H, Hedenstierna G, et al. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilatation. Anesthesiology. 1993;78:427-435.
36. Levy B, Bollaert PE, Bauer P, et al. Therapeutic optimization including nitric oxide in adult respiratory distress syndrome in a polyvalent intensive care unit. J Trauma. 1995;38:370-374.
37. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Critical Care Medicine. 1998;26:15-23.
38. McIntyre RC, Moore FA, Moore EE, et al. Inhaled nitric oxide variably improves oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. J Trauma. 1995;39:418-425.
39. Radomski MW, Moncada S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol. 1993;344:251-264.
40. Samama CM, Diaby M, Fellahi J-L, et al: Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1995;83:56-65.
41. Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol. 1992;70:18-22.
42. Albert J, Wallen NH, Broijersen A, Frosteil C, Hjemdahi P. Effects of inhaled nitric oxide compared with aspirin on platelet function in vivo in healthy subjects. Clin Sci (Colch). 1996;91:225-231.
43. Bloomfield GL, Holloway S, Ridings PC, et al. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med. 1997;25:584-593.
44. Chollet-Martin S, Gatecel C, Kermarec N, Gougerot-Pocidalo MA, Payen D. Alveolar neutrophil functions and cytokine levels during nitric oxide inhalation in patients with the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:985-990.
45. Webert KE, Vanderzwan J, Duggan M, et al. Effects of inhaled nitric oxide in a rat model of Pseudomonas aeruginosa pneumonia. Crit Care Med. 2000;28:2397-2405.
46. Lunn RJ. Inhaled nitric oxide therapy. Mayo Clin Proc. 1995;70:247-255.
47. Murray JF. Respiratory failure. In: Wingaarden JB, Smith LH, Bennett JC, eds. Cecil's Textbook of Medicine, 19th ed. Toronto: WB Saunders, 1992:472-474.
48. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg. 1996;62:1759-1764.
49. Krafft P, Fririch P, Fitzgerald RD, et al. Effectiveness of nitric oxide inhalation in septic ARDS. Chest. 1996;109:486-493.
50. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med. 1998;157:1372-1380.
51. Dupont H, Le Corre F, Fierobe L, et al. Efficiency of inhaled nitric oxide as rescue therapy during severe ARDS: survival and factors associated with the first response. J Crit Care. 1999;14:107-113.
52. Taylor RW, Zimmerman JL, Dellinger RP. Low-dose inhaled nitric oxide in patients with acute lung injury. JAMA. 2004;291:1603-1609.
53. Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Inhibitory effect of prostaglandin E1 on human neutrophil function. Prostaglandins Leukot Essent Fatty Acids. 1994;51:287-291.
54. Meyer J, Theilmeier G, Aken H, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg. 1998;86:753-8.
55. Holcroft J, Vassar M, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. Ann Surg. April 1986;203(4):371-378.
56. Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1999;27(8):1478-1485.
57. Vincent JL, Brase R, Santman F, et al. A multi-centre, double blind, placebo-controlled study of liposomal prostagladin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 27(10):1578-1583, 2001 Oct.
58. Abraham E, Park YC, Covington P, et al. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter trial. Crit Care Med. 1996;24:10-15.
59. Kaza AK, Cassada, DC Fiser SM, Long SM III, Tribble CG. The cardiovascular system. In: Oleary JP, Capote LR, eds. The Physiologic Basis of Surgery, 3rd Ed. Philadelphia: Lippincott Williams & Wilkins;2002:389-417.
60. Rose F, Zwick K, Ardeschir H, et al. Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells. Am J Respir Crit Care Med. 1999;160:846-851.
61. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. NEJM. 1993;328(6):399-405.
62. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostaglandin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996.
63. Zwissler B, Kemming G, Kleen M, et al. Inhaled prostacyclin (PG12) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:1671-7.
64. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med. 2001;29:57-62.
65. Segredo V, Matthay M, Sharma M, et al. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology. 1990;72:566-570.
66. Christensen BV, Thunedborg LP. Use of sedatives, analgesics and neuromuscular blocking agents in Danish ICUs 1996/97. A national survey. Intensive Care Med. 1999;25:186-191.
67. Klessig HT, Geiger HJ, Murray MJ, Coursin DB. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med. 1992;20:1341-1345.
68. Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure: a national survey. JAMA. 1991;266:2870-2875.
69. Bion JF, Ledingham IM. Sedation in intensive care: a postal survey. Intensive Care Med. 1987;13:215-216.
70. Viale JP, Annat GJ, Bouffard YM, Delafosse BX, Bertrand OM, Motin JP. Oxygen cost of breathing in postoperative patients. Pressure support ventilation vs continuous positive airway pressure. Chest. 1988;93:506-509.
71. Field S, Kelly SM, Macklem PT. The oxygen cost of breathing in patients with cardiorespiratory disease. Am Rev Respir Dis. 1982;126:9-13.
72. Marini JJ, Capps JS, Culver BH. The inspiratory work of breathing during assisted mechanical ventilation. Chest. 1985;87:612-618.
73. Viires N, Sillye G, Aubier M, Rassidakis A, Roussos C. Regional blood flow distribution in dog during induced hypotension and low cardiac output. Spontaneous breathing versus artificial ventilation. J Clin Invest. 1983;72:935-947.
74. Hussain SN, Roussos C. Distribution of respiratory muscle and organ blood flow during endotoxic shock in dogs. J Appl Physiol. 1985;59:1802-1808.
75. Magder S, Erian R, Roussos C. Respiratory muscle blood flow in oleic acid-induced pulmonary edema. J Appl Physiol. 1986;60:1849-1856.
76. Vernon DD, Witte MK. Effect of neuromuscular blockade on oxygen consumption and energy expenditure in sedated, mechanically ventilated children. Crit Care Med. 2000;28:1569-1571.
77. Freebairn RC, Derrick J, Gomersall CD, Young RJ, Joynt GM. Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed-loop, vecuronium infusion in severe sepsis and septic shock. Crit Care Med. 1997;25:72-77.
78. Greenough A, Wood S, Morley CJ, et al. Pancuronium prevents pneumothoraces in ventilated premature babies who actively expire against positive pressure inflation. Lancet. 1984;1:1-3.
79. Marik PE, Kaufman D. The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients. Chest. 1996;109:1038-1042.
80. Barton RG, Craft WB, Mone MC, et al. Chemical paralysis reduces energy expenditure in patients with burns and severe respiratory failure treated with mechanical ventilation. J Burn Care Rehabil. 1997;18:461-464.
81. Vernon DD, Witte MK. Effect of neuromuscular blockade on oxygen consumption and energy expenditure in sedated, mechanically ventilated children. Crit Care Med. 2000;28:1569-1571.
82. Clifton GL, Robertson CS, Choi SC. Assessment of nutritional requirements of head-injured patients. J Neurosurg. 1986;64:895-901.
83. Bruder N, Raynal M, Pellissier D, et al. Influence of body temperature, with or without sedation, on energy expenditure in severe head-injured patients. Crit Care Med. 1998;26:568-572.
84. Morris RB, Cahalan MK, Miller RD, et al. The cardiovascular effects of vecuronium (Org NC45) and pancuronium in patients undergoing coronary artery bypass grafting. Anesthesiology. 1983;58:438-440.
85. Fisher DM, Canfell PC, Fahey MR, et al. Elimination of atracurium in humans: contribution of Hofmann elimination and ester hydrolysis versus organ based elimination. Anesthesiology. 1986;65:6-12.
86. Parker CJR, Jones JE, Hunter JM. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients with renal and respiratory failure in an ITU. Br J Anaesth. 1988;61:531-540.
87. Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. NEJM. 1992;327:524-528.
88. Sharpe MD. The use of muscle relaxants in the intensive care unit. Can Anaesth Soc J. 1992;39:949-962.
89. Segredo V, Matthay M, Sharma M, et al. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology. 1990;72:566-570.
90. Shapiro BA, Warren J, Egol AB, et al. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: an executive summary. Society of Critical Care Medicine. Crit Care Med. 1995;23:1601-1605.
91. Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142-156.
92. Bryan A. Comments of a devil's advocate. Am Rev Respir Dis. 1974;110:143-144.
93. Piehl MA, Brown RS. Use of extreme position changes in acute respiratory failure. Crit Care Med. 1976;4:13-14.
94. Gattinoni L, Pesenti A, Torresin A, et al. Adult respiratory distress syndrome profiles by computed tomography. J Thorac Imaging. 1986;1:25-30.
95. Gattinoni L, Pelosi P, Vitale G, et al. Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure. Anesthesiology. 1991;74:15-23.
96. Lamm WJE, Graham MM, Albert RK. Mechanism by which the prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med. 1994;150:184-193.
97. Pappert D, Rossaint R, Slama K, Grüning T, Falke KJ. Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. Chest. 1994;106:1511-1516.
98. Beck KC, Rehder K. Differences in regional vascular conductances in isolated dog lungs. J Appl Physiol. 1986;61:530-538.
99. Glenny RW, Lamm WJE, Albert RK, Robertson HT. Gravity is a minor determinant of pulmonary blood flow distribution. J Appl Physiol. 1991;71:620-629.
100. Nyren S, Mure M, Jacobson H, Larsson SA, Lindahl SGE. Pulmonary perfusion is more uniform in the prone than in the supine position: scintigraphy in healthy humans. J Appl Physiol. 1999;86:1135-1141.
101. Malbouisson L, Busch C, Puybasset L, Lu Q, Cluzel P, Rouby J. Role of the heart in the loss of aeration characterizing lower lobes in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;161:2005-2012.
102. Albert R, Hubmayer R. The prone position eliminates compression of the lungs by the heart. Am J Respir Crit Care Med. 2000;161:1660-1665.
103. Jolliet P, Bulpa P, Chevrolet JC. Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome. Crit Care Med. 1998;26:1977-1985.
104. Mutoh T, Guest RJ, Lamm WJE, et al. Prone position alters the effect of volume overload on regional pleural pressures and improves hypoxemia in pigs in vivo. Am Rev Respir Dis. 1992;146:300-306.
105. Langer M, Mascheroni D, Marcolin R, Gattinoni L. The prone position in ARDS patients. Chest. 1988;94:103-107.
106. Krayer S, Rehder K, Vettermann J, Dider EP, Ritman EL. Position and motion of the human diaphragm during anesthesia paralysis. Anesthesiology. 1989;70:891-98.
107. Broccard AF, Shapiro RS, Schmitz LL, Ravenschaft S, Marini JJ. Influence of prone position on the extent and distribution of lung injury in a high tidal volume oleic acid model of acute respiratory distress syndrome. Crit Care Med. 1997;25:16-27.
108. Johanigman JA, Davis K, Miller SL, et al. Prone positioning for acute respiratory distress syndrome in the surgical intensive care unit: who, when, and how long? Surgery. 2000;128:708-716.
109. Offner PJ, Henel JB, Moore EE, Biffl WL, Frnciose RJ, Burch JM. Complications of prone ventilation in patients with multisystem trauma with fulminant acute respiratory distress syndrome. J Trauma. 2000;48:224-228.
110. Gattinoni L, Tognonil G, Pesenti A, et al. for the prone-supine study group: effect of prone positioning on the survival of patients with acute respiratory failure. NEJM. 2001;345:568-573.
111. Rialp G, Betbese AJ, Perez-Marquez M, Mancebo J. Short-term effects of inhaled nitric oxide and prone position in pulmonary and extrapulmonary acute respiratory distress syndrome. Am J Respir Crit Care Med. 2000;164:243-249.
112. Fridrich P, Krafft P, Hochleuthner H, Mauritz W. The effects of long-term prone positioning in patients with trauma-induced adult respiratory distress syndrome. Anesth Analg. 1996;83:1206-1211.
113. Marik PE, Iglesias J. A prone dependent patient with severe adult respiratory distress syndrome. Crit Care Med. 1997;25:1085-1087.
114. Mure M, Martling CR, Lindahl SG. Dramatic effect on oxygenation in patients with severe acute lung insufficiency treated in the prone position. Crit Care Med. 1997;25:1539-1544.
115. Hormann C, Benzer H, Baum M, et al. The prone position in ARDS. A successful therapeutic strategy. Anaesthesist. 1994;43:454-462.
116. Chatte G, Sab J, Dubois J, et al. Prone position in mechanically ventilated patients with severe acute respiratory failure. Am J Respir Crit Care Med. 1997;155:473-478.
117. Nakos G, Tsangaris I, Kostanti E, et al. Effect of the prone position on patients with hydrostatic pulmonary edema compared with patients with acute respiratory distress syndrome and pulmonary fibrosis. Am J Respir Crit Care Med. 2000;161:360-368.
118. Johannigman JA, Davis K Jr., Miller SL, et al. Prone positioning and inhaled nitric oxide: synergistic therapies for acute respiratory distress syndrome. J Trauma. 2001;50:589-596.
119. Davis K Jr., Johannigman JA, Campbell RS, et al. The acute effects of body position strategies and respiratory therapy in paralyzed patients with acute lung injury. Critical Care. 2001;5:81-87.
120. Stocker R, Neff T, Stein S, Ecknauer E, Trentz O, Russi E. Prone positioning and low-volume pressure-limited ventilation improve survival in patients with severe ARDS. Chest. 1997;111:1008-1017.
121. Ware LB, Matthay MA. The acute respiratory distress syndrome. NEJM. 2000;342:1334-1349.
122. Meduri GU. Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in unresolving ARDS. Chest 1999;116(supp):116s-118s.
123. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA. 1998;280:159-165.
124. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720-723.
125. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med. 1998;158:1432-41.
126. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med. 2002;165:983-991.
127. Zapol WM, Snider MT, Hill JD, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure? A randomized study. JAMA. 1979;242:2193-2196.
128. Morris AH, Wallace CJ, Menlove RL, et al. Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. AM J Respir Crit Care Med. 1994;149:295-305.
129. Lewandowski K, Rossaint R, Pappert D, et al. High rate in 122 ARDS patients managed according to a clinical algorithm including extracorporeal membrane oxygenation. Intensive Care Med. 1997;23:819-835.
130. Kolla S, Awad SS, Rich PB, Schreiner RJ, Hirschl RB, Bartlett RH. Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg. 1997;226:544-64.
131. Micheals AJ, Schriener RJ, Kolla S, et al. Extracorporeal life support in pulmonary failure after trauma. J Trauma. 1999;46:638-645.
132. Marini JJ, Gattinoni L. Ventilatory management of acute respiratory distress syndrome: a consensus of two. Crit Care Med. 2004;32:250-255.